

All participants (applicant, applicant's representative, PTO personnel):

(1) MINH-TAM DAVIS.

(3)\_\_\_\_\_.

(2) ANDREA GASHLER.

(4)\_\_\_\_\_.

Date of Interview: 08 April 2004.

Type: a) ☒ Telephonic b) ☐ Video Conference  
c) ☐ Personal [copy given to: 1) ☐ applicant 2) ☐ applicant's representative]

Exhibit shown or demonstration conducted: d) ☐ Yes e) ☐ No.  
If Yes, brief description: \_\_\_\_\_.

Claim(s) discussed: \_\_\_\_\_.

Identification of prior art discussed: \_\_\_\_\_.

Agreement with respect to the claims f) ☐ was reached. g) ☐ was not reached. h) ☐ N/A.

Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: See Continuation Sheet.

(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)

THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.

agreement was reached, or any other comments: 1) Claim 26 would be rejected under 112, first paragraph for an amino acid sequence having one or more conservatively substitutions relative to SEQ ID NO:2, 2) If claim 26 were amended to delete the conservative substituted sequence, Claim 26 would be in conditions for allowance, and claim 21 would be rejoined with claim 26, and would be allowable if it is amended as follows: A method for diagnosing prostate cancer in an individual, comprising a) obtaining a sample of prostate tissue from said individual, b) measuring protein level of SEQ ID NO:2 in said sample, and c) comparing said protein level to a control protein level of SEQ ID NO:2 in normal prostate tissue, wherein a sample protein level of SEQ ID NO:2 of 2- fold or more greater than said control protein level indicates the presence of prostate cancer . Applicant however declines the offer